The impact of misclassification errors on the performance of biomarkers based on next-generation sequencing, a simulation study.

Abstract excerpt

The development of next-generation sequencing (NGS) opens opportunities for new applications such as liquid biopsy, in which tumor mutation genotypes can be determined by sequencing circulating tumor DNA after blood draws. However, with highly diluted samples like those obtained with liquid biopsy, NGS invariably introduces a certain level of misclassification, even with improved technology. Recently, there has...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Algorithms
• Share to Biomarkers, Tumor
• Share to Circulating Tumor DNA